Format

Send to

Choose Destination
Anticancer Res. 2008 Jan-Feb;28(1B):415-8.

High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.

Author information

1
Department of Neurological Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. iwadatey@faculty.chiba-u.jp

Abstract

BACKGROUND:

No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis.

PATIENTS AND METHODS:

To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 glioma patients and 34 healthy volunteers.

RESULTS:

We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p = 0.0009, unpaired t-test) and those with low-grade tumors (p = 0.0074). Furthermore, high-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels (p = 0.0082). Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels.

CONCLUSION:

These results suggest that the serum PAI-1 level can be a marker for the prediction of histological grade in intracerebral glioma.

PMID:
18383878
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center